BioSpace News Archive

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced the Company will present a corporate overview and host investor meetings at the SVB Securities Global Biopharma Conference and present on Thursday, February 16, 2023, at 12:00 p.m. ET/9:00 a.m. PT.

Axcella Therapeutics (Nasdaq: AXLA) today announced that CEO Bill Hinshaw will present a company update at SVB Securities’ 2023 Global Biopharma Conference, taking place virtually February 14-16, 2023.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of data from a prospective, multicenter study, called DECIDE

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2022 after the market closes on Tuesday, February 28, 2023.

Everest Medicines (HKEX 1952.HK) announced today that South Korea’s Ministry of Food and Drug Safety (MFDS) has granted Global Innovative product on Fast Track (GIFT) designation to Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN).

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.

InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announces it has submitted a Form 12b-25 with the U.S. Securities and Exchange Commission in connection with its Quarterly Report on Form 10-Q for the period ended December 31, 2022.

BriaCell Therapeutics Corp. is pleased to announce the results of its annual general and special meeting of shareholders of the Company for the year ended July 31, 2022 held on February 9, 2023.